HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1

被引:37
作者
Busch, Chia-Jung [1 ]
Kriegs, Malte [2 ]
Laban, Simon [1 ]
Tribius, Silke [3 ]
Knecht, Rainald [1 ]
Petersen, Cordula [3 ]
Dikomey, Ekkehard [2 ]
Rieckmann, Thorsten [2 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Otolaryngol & Head & Neck Surg, D-20246 Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Lab Radiobiol & Expt Radiooncol, D-20246 Hamburg, Germany
[3] Univ Med Ctr Hamburg Eppendorf, Dept Radiotherapy & Radiooncol, D-20246 Hamburg, Germany
关键词
HPV; p16; HNSCC; Chk1; G2-arrest; Radiosensitivity; DNA-DAMAGE CHECKPOINT; HUMAN-PAPILLOMAVIRUS; KINASE; PF-00477736; CARCINOMA; THERAPY; CANCER;
D O I
10.1016/j.radonc.2013.06.035
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Despite the comparably high cure rates observed for HPV-positive HNSCC, there is still a great need for specific tumor radiosensitization due to the often severe side effects resulting from intense radiochemotherapy. We recently demonstrated that HPV-positive HNSCC cell lines are characterized by a defect in DNA double-strand break repair associated with a pronounced G2-arrest. Here we tested whether abrogation of this radiation-induced G2-arrest by the inhibition of Chk1 results in specific radisensitization of HPV-positive HNSCC cells. Materials and methods: Experiments were performed with five HPV and p16-positive (93-VU-147T, UM-SCC-47, UT-SCC-45, UD-SCC-2, UPCI-SCC-154) and two HPV and p16-negative HNSCC cell lines, as well as two normal human fibroblast strains. Chk1 was inhibited by the selective inhibitor PF-00477736. Cell cycle distribution was determined by flow cytometry, Chk1-activity via Western blot and cell survival by colony formation assay. Results: With the exception of UPCI-SCC-154, the inhibition of Chk1 was found to abolish the pronounced radiation-induced G2-arrest in all HPV-positive cells utilized. All tumor cell lines that demonstrated the abrogation of G2-arrest also demonstrated radiosensitization. Notably, in G1-arrest-proficient normal human fibroblasts no radiosensitization was induced. Conclusion: Abrogation of the G2 checkpoint through the inhibition of Chk1 may be used to selectively increase the cellular radiosensitivity of HPV-positive HNSCC without affecting the surrounding normal tissue. (C) 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 108 (2013) 495-499
引用
收藏
页码:495 / 499
页数:5
相关论文
共 50 条
  • [11] HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity
    Rieckmann, Thorsten
    Tribius, Silke
    Grob, Tobias J.
    Meyer, Felix
    Busch, Chia-Jung
    Petersen, Cordula
    Dikomey, Ekkehard
    Kriegs, Malte
    RADIOTHERAPY AND ONCOLOGY, 2013, 107 (02) : 242 - 246
  • [12] The Role of Human Chorionic Gonadotropin Beta (hCGβ) in HPV-Positive and HPV-Negative Oropharyngeal Squamous Cell Carcinoma
    Sjoblom, Anni
    Carpen, Timo
    Stenman, Ulf-Hakan
    Jouhi, Lauri
    Haglund, Caj
    Syrjanen, Stina
    Mattila, Petri
    Makitie, Antti
    Hagstrom, Jaana
    CANCERS, 2022, 14 (12)
  • [13] Preclinical trial comparing radiotherapy alone versus standard radiochemotherapy in three human papilloma virus (HPV) negative and three HPV-positive head and neck squamous cell carcinoma (HNSCC) xenograft tumour models
    Valentini, Chiara
    Ebert, Nadja
    Koi, Lydia
    Pfeifer, Manuel
    Loeck, Steffen
    Erdmann, Christoph
    Krause, Mechthild
    Baumann, Michael
    RADIOTHERAPY AND ONCOLOGY, 2023, 183
  • [14] Dual Inhibition of PARP and the Intra-S/G2 Cell Cycle Checkpoints Results in Highly Effective Radiosensitization of HPV-Positive HNSCC Cells
    Hintelmann, Katharina
    Berenz, Thomas
    Kriegs, Malte
    Christiansen, Sabrina
    Gatzemeier, Fruzsina
    Struve, Nina
    Petersen, Cordula
    Betz, Christian
    Rothkamm, Kai
    Oetting, Agnes
    Rieckmann, Thorsten
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [15] Carcinoma-associated Fibroblasts are a Common Finding in the Microenvironment of HPV-positive Oropharyngeal Squamous Cell Carcinoma
    Rahrotaban, Sedigheh
    Mahdavi, Nazanin
    Abdollahi, Alireza
    Yazdani, Farzad
    Kaghazloo, Ali
    Derakhshan, Samira
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2019, 27 (09) : 683 - 688
  • [16] Unusual presentation of HPV-positive squamous cell carcinoma of the nasolacrimal duct as carcinoma of unknown primary
    Mokhtari, Tara E.
    Warinner, Chloe
    Edwards, Heather
    Chan, Annie W.
    Annino, Don
    Schoenfeld, Jonathan D.
    Sethi, Rosh K. V.
    Rettig, Eleni M.
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2022, 43 (03)
  • [17] p16 immunohistochemistry for primary tumor detection in HPV-positive squamous cell carcinoma of unknown primary
    Shan, Alan
    Rooper, Lisa M.
    Ryan, John F.
    Eisele, David W.
    Fakhry, Carole
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2021, 42 (05)
  • [18] ATM Pathway Is Essential for HPV-Positive Human Cervical Cancer-Derived Cell Lines Viability and Proliferation
    Abjaude, Walason
    Prati, Bruna
    Munford, Veridiana
    Montenegro, Aline
    Lino, Vanesca
    Herbster, Suellen
    Rabachini, Tatiana
    Termini, Lara
    Menck, Carlos Frederico Martins
    Boccardo, Enrique
    PATHOGENS, 2022, 11 (06):
  • [19] Increased radiosensitivity of HPV-positive head and neck cancer cell lines due to cell cycle dysregulation and induction of apoptosis
    Arenz, Andrea
    Ziemann, Frank
    Mayer, Christina
    Wittig, Andrea
    Dreffke, Kirstin
    Preising, Stefanie
    Wagner, Steffen
    Klussmann, Jens-Peter
    Engenhart-Cabillic, Rita
    Wittekindt, Claus
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 (09) : 839 - 846
  • [20] In vitro effects of gamma-secretase inhibition in HPV-positive and HPV-negative head and neck squamous cell carcinoma
    Varatanovic, Sara
    Maier, Tobias
    Al-Gboore, Sega
    Stoiber, Stefan
    Kandathil, Sam Augustine
    Quint, Clemens
    Brennus, Charlotte
    Heiduschka, Gregor
    Kadletz-Wanke, Lorenz
    Brkic, Faris F.
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (02) : 193 - 201